Recent advances in anaplastic thyroid cancer management
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Anastasios Maniakas(The University of Texas MD Anderson Cancer Center)
Cited by 13
Related Papers
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid Carcinoma
|Thyroid|2024|72
Toxicity in the era of immune checkpoint inhibitor therapy
|Frontiers in Immunology|2024|56
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
|Frontiers in Endocrinology|2023|49
Initial Management of <i>BRAF </i>V600E-Variant Anaplastic Thyroid Cancer
|JAMA Oncology|2024|35
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
|Journal of the Endocrine Society|2022|22